Zentalis Pharmaceuticals (ZNTL) Free Cash Flow (2019 - 2026)

Zentalis Pharmaceuticals' Free Cash Flow history runs 8 years deep, the most recent figure standing at -$33.0 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 1.08% year-over-year to -$33.0 million in Q1 2026; TTM through Mar 2026 was -$125.6 million, a 17.21% increase from a year earlier, with the FY2025 full-year figure at -$125.2 million, up 26.79% from the prior year.
• Free Cash Flow fell to -$33.0 million in Q1 2026 per ZNTL's latest filing, from -$30.9 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$27.0 million in Q3 2025 and bottomed at -$79.6 million in Q2 2023.
• The 5-year median for Free Cash Flow is -$38.8 million (2023), against an average of -$41.4 million.
• Across the five-year window, Free Cash Flow tumbled 85.57% in 2023 and surged 55.62% in 2024, its largest moves.
• Year by year, Free Cash Flow stood at -$37.5 million in 2022, then dropped by 8.76% to -$40.8 million in 2023, then rose by 2.62% to -$39.7 million in 2024, then gained by 22.07% to -$30.9 million in 2025, then decreased by 6.63% to -$33.0 million in 2026.
• Per Business Quant, the three latest ZNTL Free Cash Flow figures stand at -$33.0 million (Q1 2026), -$30.9 million (Q4 2025), and -$27.0 million (Q3 2025).